Compare Abeona Therapeutics Inc (ABEO) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Zillow Group Inc Class C — how do they compare? Abeona Therapeutics Inc trades at $7.38 (market cap $421.19M), while Zillow Group Inc Class C trades at $32.73 (market cap $7.68B). The key difference: Zillow Group Inc Class C is far larger — about 18.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| ABEO | Z | |
|---|---|---|
Market Cap | $421.19M | $7.68B |
Sector | Health | Media |
52-Week High | $7.45 | $90.35 |
52-Week Low | $4.17 | $29.41 |
Enterprise Value | $276.10M | $7.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Zillow Group (Z) trades at $33.48, down 0.8% on the day, amid mixed technical signals and ongoing securities litigation. The company shows improving fundamentals with Q2 2026 revenue growth of 18% and consecutive earnings beats, though net margins remain thin at 1.96%. Analyst consensus is divided with a $52 price target representing 55% upside potential from current levels.
While Zillow demonstrates operational improvement and strong monetization growth, significant headwinds include multiple class-action lawsuits and bearish technical indicators. The stock offers substantial upside if legal concerns resolve favorably, but near-term volatility persists due to legal overhang and competitive real estate market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
